Facebook
Twitter
LinkedIn
Forward
Clinical Brief: Advancements in Dyslipidemia Treatments and ASCVD Risk Reduction for High-Risk Individuals
This clinical brief was developed from a presentation at the 19th CMHC Annual Congress held from October 17-19, 2024 in Boston, MA. The session, “Evolving Therapies in Dyslipidemia and ASCVD Risk Reduction: Putting It All Together in High-Risk Patients,” was presented by Dr. Pamela B. Morris, Professor of Medicine, Cardiology from The Medical University of South Carolina, Charleston, SC, supported by an educational grant from Esperion Therapeutics.
Dr. Morris discussed the latest advancements in managing dyslipidemia and reducing atherosclerotic cardiovascular disease (ASCVD) risk. This comprehensive discussion focused on high-risk patients and emphasized the integration of innovative lipid-lowering therapies, such as bempedoic acid, PCSK9 inhibitors, and combination treatments, alongside traditional statin use. She provided actionable insights to enhance patient care and lessen the burden of ASCVD.
Target Audience
The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.
Learning Objectives
After completing this activity, the participant should be better able to:
- Identify patients at high or very high risk for atherosclerotic cardiovascular disease (ASCVD)
- Recognize the need for the early and adequate intensification of LDL-C lowering therapy beyond statins to address ASCVD risk.
- Illustrate how newer classes of drugs may help to overcome challenges with patient adherence or those experiencing difficulties meeting LDL-C targets.
- Select individualized treatment strategies for LDL-C lowering that prioritize the early initiation and intensification of therapy to reduce ASCVD risk according to current guidelines and evidence.
- Discuss strategies to implement patient-tailored care and shared-decision making while choosing the most adequate LLTs
Additional Information
| Attachment | Size |
|---|---|
 Downloadable Slides | 13.57 MB |
| Clinical Brief PDF | 4.91 MB |
Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Professor of Medicine, Cardiology
Paul V. Kramer Chair of Preventive Cardiology
Director, Seinsheimer Cardiovascular Health Program
The Medical University of South Carolina
Trustee, American College of Cardiology
ESTIMATED TIME TO COMPLETE ACTIVITY
0.5 hour
EDUCATIONAL GRANT SUPPORT
Supported by an educational grant from Esperion Therapeutics.
JOINT PROVIDERSHIP STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Cardiometabolic Health Congress (CMHC). Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING EDUCATION
Partners designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
PHARMACY CONTINUING EDUCATION
Partners designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-25-128-H01-P. Type of activity: Knowledge
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
DIETITIAN CONTINUING EDUCATION
This program offers 0.5 CPEUs for dietitians.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
There are no registration fees for this activity. Participation in this self-study activity should be completed in approximately 0.5 hour. To successfully complete this activity and receive CE credit, learners must follow these steps during the period from April 11, 2025 through April 11, 2026.
- Review the objectives and disclosures
- Study the educational content
- Successfully complete activity post-test(s)
- Complete the activity evaluation
You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at [email protected]. For additional information about the accreditation of this activity, please visit https://partnersed.com
DISCLOSURES
Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Dr. Morris, faculty for this educational activity, discloses the following:
- Researcher: Esperion
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Available Credit
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 CDE
- 0.50 Participation
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.